Literature DB >> 1355363

The amino-terminal peptide of HIV-1 glycoprotein 41 lyses human erythrocytes and CD4+ lymphocytes.

P W Mobley1, C C Curtain, A Kirkpatrick, M Rostamkhani, A J Waring, L M Gordon.   

Abstract

Functional studies assessed the cytolytic activity of the amino terminal peptide (FP-I; 23 residues 519-541) of the glycoprotein 41,000 (gp41) of the Human Immunodeficiency Virus Type-1 (HIV-1). Synthetically prepared FP-I efficiently hemolyzed human red blood cells at 37 degrees C, with 40% lysis at 32 microM. Kinetic studies indicated that FP-I induced maximal hemolysis in 30 min, probably through tight binding of the peptide with the red cell membrane. The Phe-Leu-Gly-Phe-Leu-Gly (residues 526-531) motif in FP-I apparently plays a critical role in lysis of red cells, since no hemolytic activity was observed for an amino-acid-substituted FP-I in which the unique Phe-Leu-Gly-Phe-Leu-Gly was converted to Ala-Leu-Gly-Ala-Leu-Gly. As neither smaller constituent peptides (e.g., residues 519-524 and residues 526-536) nor a N-terminal flanking peptide (e.g., residues 512-523) induced red cell hemolysis, the entire 23-residue (519-541) sequence of FP-I may be required for hemolytic activity. FP-I was also cytolytic with CD4(+)-bearing Hut-78 cells, with 40% lysis at approx. 150 microM. These results are consistent with an earlier hypothesis that the N-terminal peptide of gp41 may partially contribute to the in vivo cytopathic actions of HIV-1 infection (Gallaher, W.R. (1987) Cell 50, 327-328).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355363     DOI: 10.1016/0925-4439(92)90098-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Polymorphism and interactions of a viral fusion peptide in a compressed lipid monolayer.

Authors:  G Schwarz; S E Taylor
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

2.  The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix with a conserved glycine at the micelle-water interface.

Authors:  D K Chang; S F Cheng; W J Chien
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

3.  Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein.

Authors:  Larry M Gordon; Alex Nisthal; Andy B Lee; Sepehr Eskandari; Piotr Ruchala; Chun-Ling Jung; Alan J Waring; Patrick W Mobley
Journal:  Biochim Biophys Acta       Date:  2008-05-11

4.  Conformational mapping of the N-terminal peptide of HIV-1 gp41 in lipid detergent and aqueous environments using 13C-enhanced Fourier transform infrared spectroscopy.

Authors:  Larry M Gordon; Patrick W Mobley; William Lee; Sepehr Eskandari; Yiannis N Kaznessis; Mark A Sherman; Alan J Waring
Journal:  Protein Sci       Date:  2004-04       Impact factor: 6.725

5.  Chemical shift assignment and structural plasticity of a HIV fusion peptide derivative in dodecylphosphocholine micelles.

Authors:  Charles M Gabrys; David P Weliky
Journal:  Biochim Biophys Acta       Date:  2007-08-24

6.  Inhibition of human immunodeficiency virus type-1 (HIV-1) glycoprotein-mediated cell-cell fusion by immunor (IM28).

Authors:  Donatien Mavoungou; Virginie Poaty-Mavoungou; Marie-Yvonne Akoume; Brice Ongali; Elie Mavoungou
Journal:  Virol J       Date:  2005-02-11       Impact factor: 4.099

7.  Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.

Authors:  B F Haynes; L O Arthur; P Frost; T J Matthews; A J Langlois; T J Palker; M K Hart; R M Scearce; D M Jones; C McDanal
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.